GSK
NEWS
Appointment of Mr Vince Ippolito, a US-based dermatology industry leader with over 30 years of pharmaceuticals experience as President of Botanix
The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.
Biopharma companies add new leaders to executive roles and boards of directors.
The move by Vertex is part of the company’s plan to diversify its drug discovery strategies.
Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.
MorphoSys AG reports results for the first quarter of 2019.
Celgene Corporation and bluebird bio published interim data from CRB-401, their Phase I trial of bb2121, their CAR-T therapy in patients with relapsed and refractory multiple myeloma.
In its announcement, GSK said the decision to cut the two programs were made following an analysis of available research results, including interim data from an ongoing Phase I study of the flu vaccine.
The NDA was based on positive Phase III data that shows the once-a-month treatment is as effective as the daily standard of care.
JOBS
IN THE PRESS